156TiP An open-label, single-arm, phase II study evaluating the efficacy and safety of niraparib combined with radiotherapy and teriprizumab in patients with recurrent small cell lung cancer

Abstract

Our previous basic research shows that radiotherapy combined with PARP inhibitors not only has direct antitumor effect in SCLC, but also can enhance antitumor immunity. At the same time, their combination can enhance the expression of PD-L1, which is considered to have a negative role in immune response. We found that triple therapy combined with PARP inhibitor and radiation plus anti-PD-1 can significantly enhance the antitumor effect and enhance the infiltration of cytotoxic T cells and memory T cells in SCLC model with immune function.